In the published article, there was an error in the Acknowledgements statement as Krembil Foundation was accidentally omitted. The corrected statement appears below.
Statements
Acknowledgments
“This work was supported by research grants from the Canadian Institutes of Health Research (PJT-152914) and the Heart and Stroke Foundation Chair in Cardiovascular Research (END611955) to SC. We also gratefully acknowledge the generous support from the Krembil Foundation.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
carvedilol, R-carvedilol, Alzheimer’s disease, RyR2, neuronal hyperactivity
Citation
Yao J and Chen SRW (2023) Corrigendum: R-carvedilol, a potential new therapy for Alzheimer’s disease. Front. Pharmacol. 13:1125890. doi: 10.3389/fphar.2022.1125890
Received
20 December 2022
Accepted
20 December 2022
Published
12 January 2023
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
13 - 2022
Updates
Copyright
© 2023 Yao and Chen.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jinjing Yao, jinjing.yao@ucalgary.ca; S. R. Wayne Chen, swchen@ucalgary.ca
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.